Trial Profile

A Phase 1b, Open-Label, Single-Arm Study to Evaluate the Safetyand Efficacy of CMB-012 in Subjects with Chemical Burns of theCornea and/or Persistent Corneal Epithelial Defects (PCED)

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 01 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

02 Aug 2023 According to a Kala Pharamceuticals media release, Kala Pharamceuticals has changed its name to KALA BIO.
16 May 2022 According to a Kala Pharmaceuticals media release, data from this trial presented at the At the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in May 2022.
20 Mar 2022 According to a Kala Pharmaceuticals media release, data from this trial has been accepted for presentation at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 2022.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com